BR9810907A - Monoclonal and polyclonal antibodies, peptide capable of generating an antibody, immunogenic agent, nucleotide sequence, pharmaceutical composition, use of at least one antibody, diagnostic kit, and process for preparing an immunogenic agent - Google Patents

Monoclonal and polyclonal antibodies, peptide capable of generating an antibody, immunogenic agent, nucleotide sequence, pharmaceutical composition, use of at least one antibody, diagnostic kit, and process for preparing an immunogenic agent

Info

Publication number
BR9810907A
BR9810907A BR9810907-3A BR9810907A BR9810907A BR 9810907 A BR9810907 A BR 9810907A BR 9810907 A BR9810907 A BR 9810907A BR 9810907 A BR9810907 A BR 9810907A
Authority
BR
Brazil
Prior art keywords
antibody
immunogenic agent
monoclonal
generating
pharmaceutical composition
Prior art date
Application number
BR9810907-3A
Other languages
Portuguese (pt)
Inventor
Thien Ngoc Nguyen
Ultan Power
Liliane Goestch
Alain Beck
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BR9810907A publication Critical patent/BR9810907A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"ANTICORPOS MONOCLONAIS E POLICLONAIS, PEPTìDEO SUSCETìVEL DE GERAR UM ANTICORPO, AGENTE IMUNOGêNICO, SEQUêNCIA DE NUCLEOTìDEOS, COMPOSIçãO FARMACêUTICA, USO DE PELO MENOS UM ANTICORPO, KIT DE DIAGNóSTICO, E, PROCESSO PARA PREPARAR UM AGENTE IMUNOGêNICO" A presente invenção refere-se a um anticorpo policlonal ou monoclonal, dirigido contra um epítopo da proteína G de VRS correspondendo a uma sequência escolhida dentre uma das sequências de peptídeos compreendidas entre respectivamente os resíduos de aminoácidos 150-159, 176-189, 194-207 e 155-176, da sequência total da proteína G de VRS A ou B, ou as sequências apresentando pelo menos 98% de homologia."MONOCLONAL AND POLYCLONAL ANTIBODIES, PEPTIDE SUSTAINABLE OF GENERATING AN ANTIBODY, IMMUNOGENIC AGENT, NUCLEOTIDE SEQUENCES, PHARMACEUTICAL COMPOSITION, USE OF AT LEAST ONE ANTIBODY, DIAGNOSIS KIT, PROTECT AGAINST, PROTECT AGAINST, AND PROCESS AGAINST" a polyclonal or monoclonal antibody, directed against an epitope of the RSV G protein corresponding to a sequence chosen from one of the peptide sequences comprised respectively of amino acid residues 150-159, 176-189, 194-207 and 155-176, from total protein G sequence of VRS A or B, or sequences showing at least 98% homology.

BR9810907-3A 1997-07-17 1998-07-17 Monoclonal and polyclonal antibodies, peptide capable of generating an antibody, immunogenic agent, nucleotide sequence, pharmaceutical composition, use of at least one antibody, diagnostic kit, and process for preparing an immunogenic agent BR9810907A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9709079A FR2766192B1 (en) 1997-07-17 1997-07-17 EPITOPES OF RSV AND ANTIBODIES COMPRISING SAME, USEFUL IN DIAGNOSIS AND THERAPY
PCT/FR1998/001570 WO1999003987A2 (en) 1997-07-17 1998-07-17 Syncytial respiratory virus epitopes and antibodies comprising them, useful in diagnosis and therapy

Publications (1)

Publication Number Publication Date
BR9810907A true BR9810907A (en) 2000-08-01

Family

ID=9509314

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810907-3A BR9810907A (en) 1997-07-17 1998-07-17 Monoclonal and polyclonal antibodies, peptide capable of generating an antibody, immunogenic agent, nucleotide sequence, pharmaceutical composition, use of at least one antibody, diagnostic kit, and process for preparing an immunogenic agent

Country Status (8)

Country Link
EP (1) EP1003851A2 (en)
JP (1) JP2001510039A (en)
CN (1) CN1264425A (en)
AU (1) AU756110B2 (en)
BR (1) BR9810907A (en)
CA (1) CA2296736A1 (en)
FR (1) FR2766192B1 (en)
WO (1) WO1999003987A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2790959B1 (en) * 1999-03-15 2003-06-27 Pf Medicament USE OF BACTERIAL MEMBRANARY FRACTIONS WITH ADJUVANT EFFECT, THEIR PREPARATION METHODS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
GB9920000D0 (en) * 1999-08-25 1999-10-27 Imp Cancer Res Tech Polypeptides
FR2798857B1 (en) * 1999-09-23 2003-06-06 Pf Medicament USE OF AN OMPA MEMBRANE PROTEIN OF ENTEROBACTERIA ASSOCIATED WITH AN RSV IMMUNOGENIC PEPTIDE FOR THE PREPARATION OF NASAL ADMINISTRATIVE VACCINES
FR2805163A1 (en) * 2000-02-21 2001-08-24 Pf Medicament USE OF A ZWITTERGENT TYPE DETERGENT FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION
EP1174506A1 (en) 2000-06-28 2002-01-23 Stichting Dienst Landbouwkundig Onderzoek C-terminal Erns peptide and analogues thereof
FR2819810B1 (en) * 2001-01-23 2004-05-28 Pf Medicament NON-GLYCOSYL PEPTIDES DERIVED FROM RSV PROTEIN G AND THEIR USE IN A VACCINE
FR2827605B1 (en) 2001-07-20 2004-07-16 Pf Medicament NOVEL PEPTIDES DERIVED FROM RSV PROTEIN G AND THEIR USE IN A VACCINE
CA2475235C (en) * 2002-02-05 2013-04-30 Geymonat S.P.A. Production process of recombinant placental growth factor
CN100528896C (en) * 2004-02-03 2009-08-19 中国人民解放军军事医学科学院毒物药物研究所 Chimeric antigen for preventing, diagnozing and treating respiratory syncytial virus infection and its antibody
EP1768993A4 (en) * 2004-06-16 2008-07-23 Univ Johns Hopkins The cysteine-rich region of respiratory syncytial virus and methods of use therefor
CN101130765B (en) * 2006-08-21 2011-04-06 北京阿斯可来生物工程有限公司 Reagent kit for detecting syncytial virus of respiratory passage
CA2703667C (en) * 2007-10-25 2015-12-29 Lawrence M. Kauvar Anti-rsv g protein antibodies
US8846056B2 (en) 2009-08-04 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control Anti-RSV immunogens and methods of immunization
CN103163302B (en) * 2011-12-10 2015-06-03 河北菲尼斯生物技术有限公司 Oligopeptide antibody kit prepared by directional cross-coupling technology
CN106432438A (en) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 Bovine respiratory syncytial virus antigen protein
CN106432436A (en) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 Antigen protein for bovine respiratory tract syncytial virus
CN106749555A (en) * 2016-11-28 2017-05-31 烟台偌帝生物工程有限公司 A kind of bovine respiratory born of the same parents zoarium viral antigen proteins
CN106432435A (en) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 Bovine respiration syncytial virus antigen protein
CN106397547A (en) * 2016-11-28 2017-02-15 烟台偌帝生物工程有限公司 Bovine respiration syncytial virus antigen protein
CN106518988A (en) * 2016-11-28 2017-03-22 烟台偌帝生物工程有限公司 Bovine respiratory syncytial cell virus antigen protein
CN106432439A (en) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 Bovine respiratory syncytial virus antigen protein
CN106749556A (en) * 2016-11-28 2017-05-31 烟台偌帝生物工程有限公司 A kind of bovine respiratory born of the same parents zoarium viral antigen proteins
CN106432437A (en) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 Antigen protein of bovine respiration syncytial viruses
CN112409481B (en) * 2020-12-01 2024-03-26 福州捷赫生物科技有限公司 Anti-p 40 protein monoclonal antibody, cell line, preparation method and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
SE9101433D0 (en) * 1991-05-13 1991-05-13 Marianne Hansson RECOMBINANT DNA SEQUENCE AND ITS USE
FR2718452B1 (en) * 1994-04-06 1996-06-28 Pf Medicament Element of immunogen, immunogenic agent, pharmaceutical composition and method of preparation.
US6077511A (en) * 1994-08-25 2000-06-20 Instituut Voor Dierhouderij En Diergezondheid Antigenic peptide derived from the G protein of RSV for type- and subtype-specific diagnosis of respiratory syncytial virus (RSV) infection
FR2726576B1 (en) * 1994-11-07 1997-01-31 Pf Medicament PRODUCTION OF HYDROPHOBIC PEPTIDE-LIKE PEPTIDES, RECOMBINANT PEPTIDE, CORRESPONDING DNA SEQUENCE
FR2726471B1 (en) * 1994-11-07 1997-01-31 Pf Medicament PROCESS FOR IMPROVING THE IMMUNOGENICITY OF AN IMMUNOGENIC COMPOUND OR A HAPTENA AND APPLICATION TO THE PREPARATION OF VACCINES
FR2726577B1 (en) * 1994-11-07 1997-01-31 Pf Medicament PROCESS FOR OBTAINING A PEPTIDE DERIVED FROM THE SYNCITIAL RESPIRATORY VIRUS, POLYPEPTIDE AND BACTERIA EXPRESSING THE SAME, AND THEIR APPLICATIONS AS MEDICAMENTS
FR2726472B1 (en) * 1994-11-07 1997-01-31 Pf Medicament CARRIER WITH ADJUVANT EFFECT, IMMUNOGENIC COMPLEX CONTAINING THE SAME, PREPARATION METHOD THEREOF, NUCLEOTIDE SEQUENCE AND VACCINE
AUPO026596A0 (en) * 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide

Also Published As

Publication number Publication date
CA2296736A1 (en) 1999-01-28
EP1003851A2 (en) 2000-05-31
FR2766192A1 (en) 1999-01-22
WO1999003987A2 (en) 1999-01-28
WO1999003987A3 (en) 1999-04-08
CN1264425A (en) 2000-08-23
JP2001510039A (en) 2001-07-31
AU8812398A (en) 1999-02-10
AU756110B2 (en) 2003-01-02
FR2766192B1 (en) 2001-07-13

Similar Documents

Publication Publication Date Title
BR9810907A (en) Monoclonal and polyclonal antibodies, peptide capable of generating an antibody, immunogenic agent, nucleotide sequence, pharmaceutical composition, use of at least one antibody, diagnostic kit, and process for preparing an immunogenic agent
EP0994724A4 (en) Methods and compositions for impairing multiplication of hiv-1
KR910016343A (en) Serum Reactive Epitopes of Human Papillomavirus (HPV) 16 Protein
WO1995029193A3 (en) Melanoma antigens
EP2311952A3 (en) Antibodies to MRT-1 protein or fragments thereof
ATE178907T1 (en) RECEPTOR-BINDING REGION OF DIPHTHERIAL TOXIUS
KR910002897A (en) Erythropoietin (EPO) Peptides and Antibodies
AU2196592A (en) Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits
BR9712518A (en) Polypeptide, DNA molecule, expression vector, host cell, pharmaceutical composition, vaccine, fusion protein, process for detecting tuberculosis in a patient, and diagnostic kit
KR900013979A (en) Immunogenic Regions of the Human Papillomavirus Type 16 E7 Protein
EP0090581A3 (en) Small peptides with the specificity of foot and mouth disease viral antigens
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
HUP9901688A2 (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
BR9709958A (en) Polypeptides capable of forming antigen binding structures with specificity for the rhesus antigens in the dna that encodes them and the process for their preparation and use
ES2118939T3 (en) PEPTIDE FOR DIAGNOSIS AND IMMUNIZATION AGAINST T. CRUZI INFECTION.
AU9363398A (en) Hepatitis c receptor protein cd81
AU612683B2 (en) Synthetic peptides, antibodies directed against them, and the use thereof
DE69530380T2 (en) RETROPEPTIDES, ANTIBODIES AGAINST AND THEIR USE IN VACCINATION AND VITRO DIAGNOSTICS
DK0990703T3 (en) New polypeptide, its encoding DNA, and its use
BR9710849A (en) Vaccine containing a peroxy-redoxin and / or a beta-tubulin.
KR890006253A (en) Vaccines against E. coli septicaemia in poultry
CA2139518A1 (en) Antigenic regions of tlp complexes and antibodies against the same
ES2308850T3 (en) ANTIBODIES FOR ANTIGENS OF CELLS OF LANGERHANS OF MAMIFEROS AND ITS USES.
WO1997039029A3 (en) An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof
GB2299994A (en) Equine arteritis virus peptides antibodies and their use in a diagnostic test

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]